Find comprehensive information on Farxiga (dapagliflozin) for accurate clinical documentation and medical coding. Learn about Farxiga diagnoses, ICD-10 codes related to dapagliflozin use, and best practices for documenting Farxiga in patient charts. This resource provides healthcare professionals with essential details for proper coding and billing related to Farxiga prescriptions and diabetes management. Explore Farxiga side effects, dosage information, and clinical trial data to enhance patient care and ensure compliant medical records.
Also known as
Diabetes mellitus
Farxiga treats type 2 diabetes by lowering blood sugar.
Hypertensive diseases
Farxiga can also treat high blood pressure and heart failure.
Heart failure
Farxiga is used to reduce the risk of cardiovascular death and hospitalization for heart failure.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Farxiga/Dapagliflozin used for diabetes?
When to use each related code
| Description |
|---|
| Type 2 diabetes mellitus treatment |
| Heart failure with reduced ejection fraction |
| Chronic kidney disease |
Coding Farxiga (dapagliflozin) for unapproved indications poses compliance and reimbursement risks. CDI should clarify usage.
Incorrect diabetes type (1 vs 2) with Farxiga can impact medical coding accuracy and subsequent diabetes management.
Insufficient documentation of CKD stage when coding Farxiga for CKD can lead to audit denials and lost revenue.
Q: How does Farxiga (dapagliflozin) impact cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease?
A: Farxiga (dapagliflozin), an SGLT2 inhibitor, has demonstrated significant cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease. In the DECLARE-TIMI 58 trial, dapagliflozin was shown to reduce the risk of cardiovascular death or hospitalization for heart failure, a key composite endpoint, compared to placebo. This benefit was observed irrespective of pre-existing cardiovascular disease. Additionally, dapagliflozin has been shown to improve renal outcomes in this patient population. Explore how incorporating Farxiga into your treatment plan can improve outcomes for your patients with type 2 diabetes and cardiovascular disease.
Q: What are the recommended monitoring parameters for patients with type 2 diabetes initiating Farxiga therapy, specifically regarding renal function and potential adverse effects like euglycemic diabetic ketoacidosis?
A: When initiating Farxiga (dapagliflozin) therapy in patients with type 2 diabetes, close monitoring of renal function is crucial. Baseline and periodic assessment of estimated glomerular filtration rate (eGFR) and serum creatinine are recommended. Patients with pre-existing renal impairment may require dose adjustments. Furthermore, clinicians should educate patients about the signs and symptoms of euglycemic diabetic ketoacidosis (euDKA), a rare but serious adverse effect associated with SGLT2 inhibitors, including dapagliflozin. Monitoring for ketones, especially during intercurrent illness or periods of reduced caloric intake, is important. Consider implementing a patient education program on recognizing the symptoms of euDKA, such as nausea, vomiting, abdominal pain, and difficulty breathing. Early recognition and prompt treatment can minimize the risk of complications.
Patient presents for follow-up management of type 2 diabetes mellitus. The patient reports adherence to prescribed dapagliflozin (Farxiga) 10mg daily. Current A1c is 7.2%, demonstrating reasonable glycemic control. Patient denies any Farxiga side effects such as genital mycotic infections, urinary tract infections, or hypotension. Blood pressure today is 128/76 mmHg. Patient's renal function remains stable with an eGFR of 85 mL/min/1.73 m2. Assessment: Type 2 diabetes mellitus, well-controlled on current Farxiga regimen. Plan: Continue dapagliflozin 10mg daily. Educated patient on signs and symptoms of hypoglycemia and hyperglycemia, emphasizing the importance of regular blood glucose monitoring. Discussed potential adverse effects of SGLT2 inhibitors, including euglycemic diabetic ketoacidosis and the need to report any unusual symptoms promptly. Scheduled follow-up appointment in 3 months for repeat A1c and assessment of diabetes management. ICD-10-CM code E11.9, Type 2 diabetes mellitus without complications.